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Case Report
Introduction
Diabetes mellitus (DM) is a common disorder 
affecting middle-aged to older dogs and 
characterized by hyperglycemia and glycosuria 
and typical clinical symptoms such as polyuria, 
polydipsia and weight loss (1, 2). Treatment 
options, similar to those for humans, include 
insulin injection, dietary changes and exercise. 
The classification of DM in dogs follows the 
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Abstract:  Diabetes mellitus (DM) is a common disorder in middle-aged to older dogs. Treatment options, similar to those for 
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start of insulin therapy the duration of effect and glucose nadir were ideal and clinical symptoms had disappeared but hypergly-
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at a dosage of 15 mg/kg q 12 hours, to improve insulin sensitivity or possibly increasing endogenous insulin secretion. B. serrata 
supplementation led to good glycemic control. No side-effect or adverse reaction were observed during the study. 
The present case report provides the first evidence in veterinary medicine of a positive effect of dietary supplementation with bo-
swellic acids associated with traditional insulin therapy on glycemic control in a diabetic dog. A major pitfall of the study is the lack 
of a control. More extensive clinical trials are required to provide definitive evidence of B. serrata efficacy.
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scheme used in human medicine: canine diabetes 
usually resembles type 1 diabetes in humans and 
is characterized by permanent hypoinsulinemia 
and an absolute necessity for exogenous insulin 
to maintain control of glycemia and avoid 
ketoacidosis (3). Since some diabetic dogs may 
develop humoral immune responses to exogenous 
insulin resulting in treatment failure, the use of 
alternative medicine, including herbal extracts, 
represents an interesting new therapeutic strategy 
for DM in association with the traditional insulin 
therapy as reported for diabetic patients in human 
medicine (4). Herbal drugs usually used for human 
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therapies could also be administered to pets with 
chronic diseases mainly to avoid collateral effects, 
although few studies have evaluated the efficacy 
of medicinal plants in animals (5). Since ancient 
times, frankincense, the aromatic gum resin 
obtained from trees of the genus Boswellia, has 
been used in central African countries and in the 
Middle East for the prevention and treatment of 
various illnesses, especially chronic inflammatory 
diseases. Boswellia serrata is a species of the 
Burseraceae family from India, containing boswellic 
acids known to present anti-inflammatory, anti-
hepatotoxic, antioxidant, anti-hyperlipidemic and 
hypoglycemic properties (6). In particular, boswellic 
acids seem possess antileukotrienic activity, 
showing efficacy in human chronic inflammatory 
disorders like bronchial asthma (7) and Crohn’s 
disease (8). An experimental model of multiple 
low-dose streptozotocin induced type 1 diabetes 
in mice showed that hyperglycemia results from 
an autoimmune reaction against pancreatic beta 
cells. B. serrata gum resin extracts containing 
boswellic acids administered to the mice prevented 
hyperglycemia, islet inflammation, destruction of 
β-cells and increases in proinflammatory cytokines 
(9). According to a report by Schrott et al. (2014) 
(4), an alcoholic extract of the B. serrata resin in 
addition to insulin, also prevented insulitis in a 
human patient with type 1 diabetes, leading to 
a decrease of tyrosine-phosphatase antibodies. 
Therefore, the main objective of this report was to 
evaluate a new therapeutic strategy for naturally 
occurring DM in a dog based on the association 
of insulin injections with an orally administered 
extract of B. serrata to improve glycemic control.
Figure 1: Graphic timeline of 
treatment plan and treatment 
goals; at time of diagnosis (TD), 
T1, T2 and T3 a full laboratory 
control, including haemato-bio-
chemical and urine analyses, 
was done
Case presentation
A nine year old female mixed breed dog 
weighting 18 kg was referred to Bologna University 
Veterinary Teaching Hospital with a two-month 
history of weight loss and enuresis, worsened by 
polyuria and polydipsia in the last two weeks. The 
bitch had been neutered at the age of seven months 
and was housed outdoors, fed a homemade diet 
and regularly vaccinated and dewormed. On 
physical examination, the bitch was responsive, 
with normal pink mucous membranes, 39°C rectal 
temperature, normal corneal transparency and no 
abdominal abnormalities on palpation. Abdominal 
ultrasound showed only a mild diffuse liver 
impairment. All procedures were performed under 
informed consent of the owners for diagnostic and/
or therapeutic purposes. Figure 1 shows a graphic 
timeline of the different therapeutic protocols and 
clinical analyses performed in this case study. 
The hematological profile showed mild 
leucocytosis with mature neutrophilia, while 
the serum biochemistry profile reported the 
most important alterations, namely severe 
fasting hyperglycemia, hypertriglyceridemia, 
hypercholesterolemia, a moderate increase in 
alanine aminotransferase activity (ALT) and 
fructosamine and mild hypoalbuminemia. 
Urinalysis revealed marked glycosuria, proteinuria 
and albuminuria with increased urinary protein 
to creatinine ratio (UPC) and a mild ketonuria 
(Table 1). 
Based on typical clinical signs and laboratory 
findings, DM was diagnosed and the bitch was 
treated with increasing subcutaneous doses of 
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Table 1: CBC, serum biochemistry and urinalysis results for a 9 years old mixed breed dog with polyuria and 
polydipsia at the time of DM diagnosis (TD) and after food supplementation with B. serrata dry extract in addition 
to insulin therapy (T3)
 TD T3 Reference range
CBC
RBC x 1012/L 7.5 7.3 5.5-8.5
HCT fraction 0.48 0.52 0.37-0.55
HBG g/L 175 174 120-180
WBC x 109/L 23.4 8.4 6-17
PLT x 109/L 365 304 160-500
SERUM BIOCHEMISTRY    
Protein g/L 69 68 56-79
Albumin  g/L 26 32 28-37
Creatinine µmol/L 84 66 57-119
ALT µKat/L 0.97 2.17 0.33-0.92
Triglycerides mmol/L 15.65 2.09 0.34-1.35
Cholesterol mmol/L 10.02 8.60 3.63-9.06
Glucose mmol/L 29.69 6.33 3.88-6.94
Fructosamine mmol/L 0.52 0.55 0.26-0.37
URINALYSIS
Bilirubin µmol/L Negative + Negative
Ketones mmol/L 2.58 Negative Negative
Glucose mmol/L >16.65 >16.65 Negative
Protein g/L 0.3 0.3 Negative
pH 5.5 6.5 6.5-7
SG 1040 1076 >1030
WBC + Negative Negative
Blood Negative Negative Negative
Epithelial cells + +++ Negative-+
UPC 1.2 0.3 0.0-0.4
Table 2: Average glucose concentrations obtained from glycemic curves (blood glucose concentrations were 
measured before and 2, 4, 6, 8 and 10 hours after insulin injection), fasting blood glucose, blood glucose nadirs 
(obtained 8 hours after insulin injection), serum fructosamine and triglycerides concentrations, measured as 
glycemic and lipemic control indicators. Urinary protein to creatinine ratio was also determined
Average blood 
glucose (mmol/L)
Fasting blood 
glucose (mmol/L)
Blood glucose 
nadir (mmol/L)
Fructosamine 
(mmol/L)
Triglycerides 
(mmol/L) UPC
TD 26.20 29.70 18.31 0.52 15.65 1.2
T1 23.70 28.36 17.48 0.52 nd 0.5
T2 8.21 14.21 2.77 0.68 10.37 0.5
T3 5.99 6.33 5.38  0.55 2.09 0.3
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a porcine insulin zinc suspension (Caninsulin®, 
MSD Animal Health) starting from 0.2 U/kg, q 
12 hours before feeding, up to 0.6 U/kg, with an 
increase equal to 10% to the nearest unit every 
two weeks. A specific commercial restricted-fat 
high-fiber diet as the sole source of food was also 
included in the therapy. Glycemia was monitored 
using a Glucocard G+ home glucometer (Menarini 
Diagnostic) in order to obtain a weekly blood 
glucose curve. The glycemic control was considered 
good when fasting blood glucose was below 16.65 
mmol/L and the polyuria and polydipsia were 
absent, according to the owner’s observation.
At T1 the bitch was re-examined. Although there 
was a complete remission of clinical symptoms of 
diabetes and the bitch gained 1.5 kg of weight, 
with a mild improvement of fasting blood glucose 
and blood glucose nadir, no change in serum 
fructosamine level was observed. Furthermore, 
the urinalysis revealed persistent glycosuria 
though with reduced proteinuria. The target 
results for a good glycemic control according to 
the AAHA diabetes management guidelines for 
diabetic dogs (1) were established as follows: 
nadir 4.44 to 8.32 mmol/L, time of nadir 8 hours 
after insulin injection, average blood glucose < 
13.87 mmol/L, no single blood glucose > 16.65 
mmol/L. To further reduce hyperglycemia, the 
patient’s diet was supplemented every 12 hours 
with a dry extract obtained from B. serrata gum 
resin containing 300 mg of extract titrated to 65% 
in boswellic acids (15 mg/kg q 12 hours). Home 
monitoring was performed monthly and the owner 
reported a progressive improvement of glycemic 
control after four weeks of supplementation. A 
complete blood count, serum biochemistry profile 
and urinalysis were performed 26 weeks (T2) after 
the beginning of B. serrata supplementation to 
evaluate glycemic and lipemic control and the 
general health status of the bitch. At T2 blood 
glucose nadir showed a drastic drop to 2.77 
mmol/L in the absence of clinical symptoms, 
while fasting blood glucose was 14.21 mmol/L 
and UPC stably remained slightly above the 
references range. Blood triglyceride concentration 
presented a remarkable decrease, although still 
widely above the reference range (Table 2). For 
this reason, additional supplementation was 
introduced with 9 ml fish oil, every 12 hours in 
the food. Twelve weeks (T3) after the beginning of 
fish oil supplementation, glycemic control showed 
a further decrease for both fasting blood glucose 
and average blood glucose and UPC also fell 
within the range. Blood triglyceride concentration 
was reduced fivefold and was very close to the 
reference range (Table 2). Serum ALT activity 
and fructosamine concentration were above the 
reference ranges throughout the study regardless 
of glycemic control (Table 1). 
No side effects such as nausea, diarrhea or 
vomiting were observed during the study and 
no further serum and hematological parameters 
resulted altered. 
Discussion
In late stage canine diabetes type 1, loss of 
β-cell function is irreversible and lifelong insulin 
therapy is mandatory to maintain glycemic 
control of the diabetic state (10, 11). Despite the 
pharmacotherapy approved for use in diabetic 
dogs, based on the administration of a porcine 
insulin zinc suspension (12) and the existence 
of other types of insulin tested in dogs (13, 14), 
it is still difficult to achieve adequate glycemic 
control in many diabetic canine patients, due 
to many causes such as insulin resistance or 
insulin-induced hyperglycemia. Most of the 
diabetic dogs are well controlled already at 0.5 U/
Kg q 12 hours (1). Also in the case reported in 
this paper, therapy based on 0.6 U/kg q 12 hours 
of a porcine insulin zinc suspension resulted in 
the disappearance of clinical symptoms with an 
ideal duration of therapeutic effect (10 hours) and 
time of glucose nadir (8 hours post-injection). 
However, hyperglycemia, tough less severe, and 
persistent glycosuria were still present. Glycosuria 
in dogs typically develops when blood glucose 
concentration exceeds approximately 11.1 mmol/L 
and since average blood glucose in diabetic dogs 
should be less than 13.87 mmol/L, glycosuria may 
occur also in well controlled diabetic patients (1). 
In the present study, to achieve a better glycemic 
control, rather than increasing the dose of insulin, 
a food supplementation with a dry extract from 
B. serrata was introduced. This choice has the 
advantage to minimize the risk of hypoglycemia, 
which may often results in dogs with insulin 
excess or after excessive and strenuous exercise 
and to maintain the benefits obtained with the 
therapy based on 0.6 U/kg q 12 hours of insulin.
Different medicinal plants have been found 
to have a hypoglycemic effect both in normal 
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and diabetic human patients (15). Among herbal 
drugs, dry extract of the B. serrata gum resin have 
been used in traditional medicine for a variety of 
therapeutic purposes (16) without adverse effects 
or interferences with other drugs reported to date 
in experimental animals and humans (17, 18, 
19). Boswellic acids, including O-acetyl-11-ketoβ-
boswellic acid (AKBA) and 11-keto-β-boswellic 
acid (KBA), present in B. serrata gum resin, are 
novel, specific inhibitors of 5-lipoxygenase with 
a wide therapeutic potential (20). An alcoholic 
extract of B. serrata gum resin and two of its 
active compounds, AKBA and KBA, were recently 
reported to prevent hyperglycemia in multiple 
low-dose streptozotocin-induced diabetic mice 
as an animal model of type 1 DM, possibly 
by suppressing the production/action of pro-
inflammatory cytokines and preventing insulitis in 
an autoimmune process (21, 9). Moreover, Schrott 
et al. (4) observed that treatment with B. serrata 
extract in a human patient with latent autoimmune 
type 1 diabetes led to a significant decrease of 
IA2 antibodies, a typical marker of autoimmune 
diabetes used in human medicine. There is also 
evidence that B. serrata supplementation with 
900 mg/die for six weeks in human diabetes 
type 2 produces a remarkable decrease in fasting 
blood glucose (22). In the present study, clinical 
symptoms showed the typical features of canine 
diabetes and the diagnosis was achieved at a late 
stage. Therefore, it was not possible to clearly 
understand the etiopathogenesis and to classify 
the type of DM by assessing peptide C level to 
confirm an endogenous secretion of insulin, and/
or by assessing the presence of autoantibodies 
to evaluate an autoimmune reaction. However, 
the good response to insulin therapy let us 
suppose that the dog was affected by type 1 DM. 
The hypoglycemic effect of B. serrata extract, 
administered in addition to insulin therapy, was 
evident and probably due to the improvement 
of a possible remaining endogenous insulin 
secretion through its antinflammatory action in 
an autoimmune process. Moreover, B. serrata 
supplementation in human patients affected by 
diabetes type 2 produces a significant decrease 
in blood cholesterol, LDL, fructosamine, ALT and 
AST activities and increased insulin levels (22). 
ALT activity in our case was over the reference 
range throughout the study, as already described 
for different hepatic enzyme activities in diabetic 
dogs probably due to hepatic lipidosis (23). 
However, the increased ALT activity was not 
accompanied by clinical symptoms and it may 
not be associated with progressive liver damage. 
A randomized clinical trial study in human type 
2 diabetic patients, treated with 400 mg/die of 
B. serrata powder reported significantly lower 
glucose, HbA1c, insulin, total cholesterol, LDL and 
triglycerides levels with respect to a placebo group 
(24). In addition to its hypoglycemic effect, B. serrata 
could be used also as an anti-hyperlipidemic agent 
in diabetic patients (25), although in the present 
study an evident drop of serum triglycerides was 
obtained only after the administration of fish oil, as 
previously reported (26).
Despite the improvement in the glycemic 
control, the serum fructosamine concentration 
remained above the reference range throughout 
the study. This discrepancy between fructosamine 
and glucose serum concentration has already 
been reported in diabetic dogs (13, 27) and may 
be due to the delay between change in control of 
glycemia and change in blood glycated protein 
concentration. However, also specific canine 
genetic factors may influence variations in serum 
fructosamine concentration unrelated to glycemia 
as reported in Belgian Shepherds (28).
Conclusion
To the best of our knowledge, the only insulin 
preparation approved for use in dogs with DM 
is a porcine insulin zinc suspension that does 
not always provide optimal glycemic control. 
On the other hand, most DM dogs are type I 
insulin-dependent and oral hypoglycemic drugs 
are usually ineffective or accompanied by side-
effects. The present case study provides the first 
evidence in veterinary medicine of a positive effect 
of dietary supplementation with dry B. serrata 
extract associated with traditional insulin therapy 
on glycemic and lipemic control in a dog with 
naturally occurring DM. The use of B. serrata 
extract in many inflammatory diseases did not 
produce any side-effects (6, 29) and could be a 
cheap and safe DM treatment option in addition 
to insulin therapy, when insulin alone cannot 
achieve good glycemic control. 
The major pitfall of this study is the lack of a 
control case. A more extensive pharmacological 
study and interventional prospective clinical 
trials are needed to clarify the mechanism of 
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action of B. serrata extracts and to provide a 
definitive evidence of their efficacy and safety in 
the treatment of diabetes mellitus in dogs. 
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VPLIV DODAJANJA BOSVELIJE (Boswellia serrata) OB ZDRAVLJENJU Z INZULINOM 
NA UREJANJE RAVNI GLUKOZE V KRVI PRI PSU S SLADKORNO BOLEZNIJO 
G. Andreani, E. Ferlizza, E. Macrì, D. Beghelli, G. Isani
Povzetek:  Sladkorna bolezen oz. diabetes mellitus (DM) je pogosta motnja pri psih v srednjih letih in starejših psih. Možnosti 
zdravljenja, ki so podobne kot pri ljudeh, vključujejo dodajanje inzulina, spremembe v prehrani in telesno aktivnost. Ker lahko ne-
kateri psi s sladkorno boleznijo razvijejo imunski odziv na dodajanje inzulina, kar lahko vodi do neuspešnega zdravljenja, lahko 
uporaba alternativne medicine predstavlja zanimivo novo metodo zdravljenja DM poleg tradicionalnega zdravljenja z inzulinom. 
Glavni cilj raziskave je bil ovrednotiti novo metodo zdravljenja DM, ki temelji na hkratnem dodajanju inzulina in peroralnem doda-
janju izvlečka bosvelije (Boswellia serrata) za izboljšanje urejanja ravni glukoze v krvi pri psu s sladkorno boleznijo. Devet let stara 
sterilizirana samica mešane pasme, ki je bila diagnosticirana s sladkorno boleznijo, je bila zdravljena z naraščajočimi odmerki 
suspenzije prašičjega inzulina in cinka (od 0,2 E/kg do 0,6 U/kg), ki jih je dobivala vsakih 12 ur. Dvajset tednov po začetku zdravl-
jenja z inzulinom so bili učinki in najnižja vrednost izmerjene glukoze v normalnih mejah vrednosti, klinični simptomi so izginili, le hi-
perglikemija je bila še vedno prisotna, vendar pa je bila manj resna. Dodatek suhega izvlečka iz gumijeve smole bosvelije Boswe-
llia serrata v odmerku 15 mg/kg vsakih 12 ur je povečal občutljivost na inzulin oz. morebitne preostanke endogenega izločanja 
inzulina. Dodatek B. serrata je pozitivno vplival na nadzorovanje sladkorne bolezni. Med zdravljenjem niso bili opaženi stranski ali 
nezaželeni učinki. Poročilo o opisanem primeru vsebuje prve dokaze o pozitivnem učinku prehranskega dopolnila z bosveličnimi 
kislinami v veterinarski medicini, povezanimi z običajnim zdravljenjem z inzulinom, pri nadzoru glukoze v krvi pri psu s sladkorno 
boleznijo. Najbolj neugoden del te študije je odsotnost kontrole. Za zagotovitev dokončnega dokaza o učinkovitosti B. serrata so 
potrebni obsežnejši klinični poskusi.
Kljuène besede:  diabetes mellitus; pes; bosvelična kislina; nadzor sladkorne bolezni
